Acesso livre
Acesso livre

Medicina de Emergências

Parada cardíaca fora do ambiente hospitalar: passado, presente e futuro.

17 Ago, 2021 | 11:13h

Out of hospital cardiac arrest: Past, present, and future – Resuscitation

Diretriz | Abdome agudo em pacientes imunocomprometidos.

16 Ago, 2021 | 11:53h

Acute abdomen in the immunocompromised patient: WSES, SIS-E, WSIS, AAST, and GAIS guidelines – World Journal of Emergency Surgery

M-A | Abordagem da temperatura-alvo após parada cardíaca fora do ambiente hospitalar – “O uso rotineiro de hipotermia moderada ou profunda em sobreviventes comatosos pode estar potencialmente associado com mais dano do que benefício.”

16 Ago, 2021 | 11:50h

Targeted temperature management following out-of-hospital cardiac arrest: a systematic review and network meta-analysis of temperature targets – Intensive Care Medicine (gratuito por tempo limitado)

Conteúdo relacionado: RCT: In patients with coma after out-of-hospital cardiac arrest, targeted hypothermia did not improve outcomes.

 

Comentário no Twitter

 

Análise do especialista | Intervenção coronariana percutânea (PCI) para doença multiarterial no infarto do miocárdio com elevação do segmento ST (STEMI).

16 Ago, 2021 | 11:44h

PCI for Multivessel Disease in STEMI – American College of Cardiology

 

Comentários no Twitter

 

Doença de Kawasaki e síndrome inflamatória multissistêmica em crianças: uma visão geral e comparação.

13 Ago, 2021 | 12:27h

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison – American Family Physician

Conteúdos relacionados:

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Opinião | A fluvoxamina poderia ser nosso primeiro tratamento efetivo, barato e amplamente disponível para COVID-19?

13 Ago, 2021 | 12:26h

Could This Be Our First Effective, Inexpensive, Widely Available Outpatient Treatment for COVID-19? – HIV and ID Observations

Conteúdo relacionado: Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

Como a COVID-19 mudará o tratamento de outras infecções virais respiratórias.

13 Ago, 2021 | 12:21h

How COVID-19 will change the management of other respiratory viral infections – Intensive Care Medicine

 

Comentário no Twitter

 

Características clínicas da trombocitopenia e da trombose imunes induzidas por vacina.

12 Ago, 2021 | 12:21h

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis – New England Journal of Medicine

Comentário: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD

Conteúdos relacionados:

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

 

Comentário no Twitter

 

Diretrizes de 2021 para tratamento de tromboembolismo na América Latina.

12 Ago, 2021 | 12:13h

ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America – Blood Advances

Estudo randomizado PRINCIPLE | Budesonida inalatória melhora o tempo de recuperação da COVID-19 em pessoas com alto risco de complicações na comunidade.

11 Ago, 2021 | 11:02h

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet

Comentário convidado: The use of inhaled corticosteroids in early-stage COVID-19

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.